CN100536853C - β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 - Google Patents
β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 Download PDFInfo
- Publication number
- CN100536853C CN100536853C CNB038251159A CN03825115A CN100536853C CN 100536853 C CN100536853 C CN 100536853C CN B038251159 A CNB038251159 A CN B038251159A CN 03825115 A CN03825115 A CN 03825115A CN 100536853 C CN100536853 C CN 100536853C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hbv
- pharmaceutically acceptable
- host
- iss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41067502P | 2002-09-13 | 2002-09-13 | |
| US60/410,675 | 2002-09-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1777363A CN1777363A (zh) | 2006-05-24 |
| CN100536853C true CN100536853C (zh) | 2009-09-09 |
Family
ID=31994179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038251159A Expired - Lifetime CN100536853C (zh) | 2002-09-13 | 2003-09-15 | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7186700B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1572095B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4173861B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR100855907B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100536853C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003278816A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0314259A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2498731C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1572095T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2547002T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE027522T2 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1572095E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1572095T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004024095A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| SI1572095T1 (sl) * | 2002-09-13 | 2015-12-31 | Novartis Ag | Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv |
| EP1608403A2 (en) * | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| RU2358979C2 (ru) * | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
| US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| ES2725457T3 (es) | 2004-09-14 | 2019-09-24 | Gilead Pharmasset Llc | Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados |
| KR20070110901A (ko) | 2005-03-04 | 2007-11-20 | 다이나박스 테크놀로지 코퍼레이션 | 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(iss)을 갖는올리고뉴클레오티드를 포함하는 백신 |
| RU2008109649A (ru) * | 2005-08-15 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В |
| JP2010513484A (ja) * | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
| WO2008106166A2 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20090082306A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telbivudine |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| MX2011006890A (es) | 2008-12-23 | 2011-07-20 | Pharmasset Inc | Analogos de nucleosidos. |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| AP2012006535A0 (en) | 2010-03-31 | 2012-10-31 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorous containing actives |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
| CN102140534A (zh) * | 2010-12-15 | 2011-08-03 | 深圳华大基因科技有限公司 | 一种hbv基因的核苷酸突变位点的检测方法 |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| HRP20180237T4 (hr) | 2011-09-16 | 2020-12-11 | Gilead Pharmasset Llc | Metode za liječenje hcv-a |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2869554A1 (en) * | 2012-04-04 | 2013-10-10 | Duke University | Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US9688666B2 (en) * | 2013-02-07 | 2017-06-27 | Tobira Therapeutics, Inc. | Lamivudine salts |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| WO2018092728A1 (ja) | 2016-11-16 | 2018-05-24 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
| EP3596202A4 (en) | 2017-03-14 | 2021-01-27 | The Regents of the University of California | GENOME-WIDE IDENTIFICATION OF IMMUNEVASIONAL FUNCTIONS IN A VIRUS |
| US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
| WO2022010778A1 (en) | 2020-07-07 | 2022-01-13 | Tosk, Inc. | Uridine phosphorylase inhibitors to treat or prevent pulmonary disease |
| CN115607532A (zh) * | 2021-07-15 | 2023-01-17 | 上海市公共卫生临床中心 | 大黄酸在制备改善老年机体免疫功能药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1320128A (zh) * | 1998-08-10 | 2001-10-31 | 诺沃瑞尔制药有限公司 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
| US5190926A (en) * | 1987-01-28 | 1993-03-02 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents |
| GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
| EP0355131B1 (en) | 1987-10-28 | 1996-09-04 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US6020322A (en) * | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
| ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
| US5256641A (en) * | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| IT1246983B (it) | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| CA2105486C (en) | 1991-03-06 | 2003-10-28 | George Robert Painter Iii | Therapeutic nucleosides |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| CA2112803A1 (en) | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Antiviral liponucleosides: treatment of hepatitis b |
| US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| EP0691981A1 (en) | 1993-03-10 | 1996-01-17 | The Wellcome Foundation Limited | Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides |
| JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
| JPH08510236A (ja) | 1993-05-12 | 1996-10-29 | カール ワイ. ホステトラー | 局所使用のためのアシクロビル誘導体 |
| AU7954694A (en) | 1993-09-10 | 1995-03-27 | Centre National De La Recherche Scientifique (Cnrs) | Nucleosides with anti-hepatitis b virus activity |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| WO1996011204A1 (de) | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
| US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
| US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| ES2276404T3 (es) | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
| AT409815B (de) | 1995-07-11 | 2002-11-25 | Enco En Componenten Ges M B H | Anlage zur aufbereitung biogener rohstoffe |
| US6025335A (en) * | 1995-09-21 | 2000-02-15 | Lipitek International, Inc. | L-Nucleoside Dimer Compounds and therapeutic uses |
| US6242187B1 (en) * | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6194391B1 (en) * | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
| JP3959176B2 (ja) | 1998-06-25 | 2007-08-15 | 松下電器産業株式会社 | ファンモータ駆動装置 |
| US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| US6065181A (en) * | 1998-09-03 | 2000-05-23 | Cleveland; Thomas | Portable ticket scratching device with vacuum |
| AR028149A1 (es) | 1999-07-08 | 2003-04-30 | Innogenetics Nv | Deteccion de la resistencia a los farmacos contra la hepatitis b |
| US6265181B1 (en) | 1999-09-24 | 2001-07-24 | The Public Health Research Institute Of The City Of New York, Inc. | Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection |
| DE60105424T2 (de) * | 2000-05-26 | 2005-09-22 | Idenix (Cayman) Ltd. | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
| MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| AU2001269092A1 (en) * | 2000-06-27 | 2002-01-08 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| US6855346B2 (en) * | 2001-10-05 | 2005-02-15 | Tzu-Sheng Wu | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
| SI1572095T1 (sl) * | 2002-09-13 | 2015-12-31 | Novartis Ag | Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv |
-
2003
- 2003-09-15 SI SI200332444T patent/SI1572095T1/sl unknown
- 2003-09-15 JP JP2004536551A patent/JP4173861B2/ja not_active Expired - Fee Related
- 2003-09-15 PT PT37703345T patent/PT1572095E/pt unknown
- 2003-09-15 EP EP03770334.5A patent/EP1572095B1/en not_active Expired - Lifetime
- 2003-09-15 KR KR1020057004375A patent/KR100855907B1/ko not_active Expired - Lifetime
- 2003-09-15 ES ES03770334.5T patent/ES2547002T3/es not_active Expired - Lifetime
- 2003-09-15 DK DK03770334.5T patent/DK1572095T3/en active
- 2003-09-15 CA CA2498731A patent/CA2498731C/en not_active Expired - Lifetime
- 2003-09-15 AU AU2003278816A patent/AU2003278816A1/en not_active Abandoned
- 2003-09-15 HU HUE03770334A patent/HUE027522T2/en unknown
- 2003-09-15 WO PCT/US2003/029017 patent/WO2004024095A2/en not_active Ceased
- 2003-09-15 US US10/662,641 patent/US7186700B2/en not_active Expired - Lifetime
- 2003-09-15 KR KR1020087012404A patent/KR20080053419A/ko not_active Withdrawn
- 2003-09-15 BR BR0314259-0A patent/BR0314259A/pt not_active Application Discontinuation
- 2003-09-15 CN CNB038251159A patent/CN100536853C/zh not_active Expired - Lifetime
-
2007
- 2007-01-09 US US11/651,353 patent/US7928086B2/en not_active Expired - Fee Related
-
2008
- 2008-04-08 JP JP2008099992A patent/JP2008273960A/ja active Pending
-
2011
- 2011-03-21 US US13/052,750 patent/US8158606B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1320128A (zh) * | 1998-08-10 | 2001-10-31 | 诺沃瑞尔制药有限公司 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0314259A (pt) | 2005-07-26 |
| HUE027522T2 (en) | 2016-11-28 |
| ES2547002T3 (es) | 2015-09-30 |
| WO2004024095A3 (en) | 2006-02-16 |
| EP1572095A4 (en) | 2008-11-05 |
| EP1572095A2 (en) | 2005-09-14 |
| US7928086B2 (en) | 2011-04-19 |
| AU2003278816A1 (en) | 2004-04-30 |
| US20050080034A1 (en) | 2005-04-14 |
| US20110172178A1 (en) | 2011-07-14 |
| US8158606B2 (en) | 2012-04-17 |
| CN1777363A (zh) | 2006-05-24 |
| AU2003278816A8 (en) | 2004-04-30 |
| PT1572095E (pt) | 2015-10-13 |
| KR20050051662A (ko) | 2005-06-01 |
| KR20080053419A (ko) | 2008-06-12 |
| JP4173861B2 (ja) | 2008-10-29 |
| DK1572095T3 (en) | 2015-09-14 |
| JP2006516949A (ja) | 2006-07-13 |
| WO2004024095A2 (en) | 2004-03-25 |
| JP2008273960A (ja) | 2008-11-13 |
| US7186700B2 (en) | 2007-03-06 |
| CA2498731A1 (en) | 2004-03-25 |
| EP1572095B1 (en) | 2015-06-10 |
| KR100855907B1 (ko) | 2008-09-02 |
| SI1572095T1 (sl) | 2015-12-31 |
| US20080182814A1 (en) | 2008-07-31 |
| CA2498731C (en) | 2012-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2498731C (en) | .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies | |
| CN100490818C (zh) | β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途 | |
| JP4294870B2 (ja) | B型肝炎の治療のためのβ−L−2’−デオキシ−ヌクレオシド | |
| EP4319763A2 (en) | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses | |
| ES3018133T3 (en) | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae | |
| EP3732180A1 (en) | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents | |
| JP2007204485A (ja) | 抗b型肝炎ウィルス活性を有するヌクレオシド | |
| TW202140789A (zh) | 靶向pd—l1之方法及組合物 | |
| CN114867351A (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| JP2003528138A (ja) | デルタ肝炎ウイルス感染症の治療法 | |
| JP2022523423A (ja) | 2’3’-環状ジヌクレオチドおよびそのプロドラッグ | |
| WO2004006848A2 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection | |
| CN101120947B (zh) | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 | |
| HK1050999B (en) | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER OWNER: EDENNICKS (CAYMAN) CO., LTD. Effective date: 20090925 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090925 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Cayman Islands Patentee before: Idenix Cayman Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181213 Address after: Hertfordshire Patentee after: Mailan Holdings Co.,Ltd. Address before: Basel, Switzerland Patentee before: Novartis AG |
|
| CX01 | Expiry of patent term |
Granted publication date: 20090909 |
|
| CX01 | Expiry of patent term |